Phase 3 N=164 A Study on Visco-antalgic Intra-articular Administration in Symptomatic Knee Osteoarthritis
Knee Osteoarthritis
Primary: Change From Baseline in WOMAC VA3.1 Pain Subscale Score at Month 6 — -23.6; -14.1 mm — p=0.141
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=549 Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS) ( ULTIMATE 1 )
Relapsing Multiple Sclerosis (RMS)
Primary: Annualized Relapse Rate (ARR) — 0.076; 0.188 relapses per participant-years — p=<0.0001
Phase 3 N=545 Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS)
Relapsing Multiple Sclerosis (RMS)
Primary: Annualized Relapse Rate (ARR) — 0.091; 0.178 relapses per participant-years — p=0.0022
Phase 3 N=66 Acceptance and Commitment Training for Adolescents and Young Adults With Neurofibromatosis Type 1, Plexiform Neurofibromas, and Chronic Pain
Neurofibromatosis Type 1 · Plexiform Neurofibromas
Primary: Mean Pain Interference Mean Score Change From Baseline to 8 Weeks Between the Acceptance and Commitment Therapy Intervention Group and the Waitlist Group — 61.93; 62.87…
Phase 3 N=168 Safety and Efficacy of NP-120 (Ifenprodil) for the Treatment of Hospitalized Patient With Confirmed COVID-19 Disease
COVID
Primary: Patient Clinical Status (on the WHO 7-point Ordinal Scale) at Day 15 in IP Versus SOC Control Group Patients: — 10; 9; 18; 7 Participants — p=<0.025
Phase 3 N=105 KIDCARE (Kawasaki Disease Comparative Effectiveness Trial)
Mucocutaneous Lymph Node Syndrome
Primary: Number of Participants With Cessation of Fever Within 24h of Initiation of Study Treatment With no Fever Recurrence Within Next 7 Days. — 25; 40 Participants
Phase 3 N=2,964 Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Dialysis (ASCEND-D)
Anaemia · Aspergillosis, Allergic Bronchopulmonary
Primary: Time to First Occurrence of Adjudicated Major Adverse Cardiovascular Event (MACE) During Cardiovascular (CV) Events Follow-up Time Period: Non-inferiority Analysis…
Phase 3 N=317 A Study to Evaluate the Efficacy and Safety of Lenalidomide as Maintenance Therapy for Patients With B-Cell Chronic Lymphocytic Leukemia (CLL) Following Second Line Therapy
B-cell Chronic Lymphocytic Leukemia
Primary: Overall Survival (OS) — 95.09; 73.28 Months — p=0.276
Phase 3 N=424 A Study of S6G5T-3 in the Treatment of Acne Vulgaris
Acne Vulgaris
Primary: Percentage of Participants Achieving an IGA Score of Clear or Almost Clear and a Score ≥2 Grades Less Than Baseline — 38.5; 11.5 percentage of participants
Phase 3 N=535 A Study Comparing Estradiol Vaginal Cream to Estrace® Cream in Females With Atrophic Vaginitis
Atrophic Vaginitis
Primary: Vaginal Cytology — 29; 19; 0 participants
Phase 3 N=48 Ketorolac as an Adjuvant Agent for Postoperative Pain Control Following Arthroscopic Meniscus Surgery
Meniscus Tear, Tibial · Pain, Postoperative · Postoperative Complications
Primary: Pain Levels Recorded With a Visual Analogue Scale — 25.6; 28.8 score on a scale
Phase 3 N=368 Double Cord Versus Haploidentical (BMT CTN 1101)
Acute Lymphocytic Leukemia · Acute Myelogenous Leukemia · Burkitt's Lymphoma
Primary: Percentage of Participants With Progression Free Survival (PFS) — 35.0; 41.1 percentage of participants — p=0.4092
Phase 3 N=434 A Study of S6G5T3 in the Treatment of Acne Vulgaris
Acne Vulgaris
Primary: Percentage of Participants Achieving an IGA Score of Clear or Almost Clear and a Score ≥2 Grades Less Than Baseline — 25.4; 14.7 percentage of participants
Phase 3 N=464 Trial for the Treatment of Extensively Drug-Resistant Gram-negative Bacilli (OVERCOME)
Pneumonia · Blood Stream Infection
Primary: Mortality — 92; 78; 122; 133 Participants — p=0.21
Phase 3 N=88 Apixaban for Early Prevention of Recurrent Embolic Stroke and Hemorrhagic Transformation
Transient Ischemic Attack · Stroke · Atrial Fibrillation
Primary: Number of Participants With a Composite Endpoint of Fatal Stroke, Recurrent Ischemic Stroke, or TIA — 7; 12 Participants